These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 34740314)

  • 1. Nuclear receptors: a bridge linking the gut microbiome and the host.
    Wang Z; Chen WD; Wang YD
    Mol Med; 2021 Nov; 27(1):144. PubMed ID: 34740314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Bile Acids in Metabolic Control.
    Molinaro A; Wahlström A; Marschall HU
    Trends Endocrinol Metab; 2018 Jan; 29(1):31-41. PubMed ID: 29195686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
    Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
    J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of bile acids in liver diseases mediated by the gut microbiome.
    Shao JW; Ge TT; Chen SZ; Wang G; Yang Q; Huang CH; Xu LC; Chen Z
    World J Gastroenterol; 2021 Jun; 27(22):3010-3021. PubMed ID: 34168404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk between Bile Acids and Gut Microbiota and Its Impact on Farnesoid X Receptor Signalling.
    Wahlström A; Kovatcheva-Datchary P; Ståhlman M; Bäckhed F; Marschall HU
    Dig Dis; 2017; 35(3):246-250. PubMed ID: 28249261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism.
    Duparc T; Plovier H; Marrachelli VG; Van Hul M; Essaghir A; Ståhlman M; Matamoros S; Geurts L; Pardo-Tendero MM; Druart C; Delzenne NM; Demoulin JB; van der Merwe SW; van Pelt J; Bäckhed F; Monleon D; Everard A; Cani PD
    Gut; 2017 Apr; 66(4):620-632. PubMed ID: 27196572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiome and health: mechanistic insights.
    de Vos WM; Tilg H; Van Hul M; Cani PD
    Gut; 2022 May; 71(5):1020-1032. PubMed ID: 35105664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Bacterial Metabolites on Gut Barrier Function and Host Immunity: A Focus on Bacterial Metabolism and Its Relevance for Intestinal Inflammation.
    Gasaly N; de Vos P; Hermoso MA
    Front Immunol; 2021; 12():658354. PubMed ID: 34122415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between Host PPARs and Gut Microbiota in Health and Disease.
    Hasan AU; Rahman A; Kobori H
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders.
    Fiorucci S; Distrutti E
    Trends Mol Med; 2015 Nov; 21(11):702-714. PubMed ID: 26481828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice.
    Zheng X; Huang F; Zhao A; Lei S; Zhang Y; Xie G; Chen T; Qu C; Rajani C; Dong B; Li D; Jia W
    BMC Biol; 2017 Dec; 15(1):120. PubMed ID: 29241453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consequences of bile salt biotransformations by intestinal bacteria.
    Ridlon JM; Harris SC; Bhowmik S; Kang DJ; Hylemon PB
    Gut Microbes; 2016; 7(1):22-39. PubMed ID: 26939849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis.
    Li H; Xi Y; Xin X; Tian H; Hu Y
    Biomed Pharmacother; 2020 Apr; 124():109915. PubMed ID: 31986416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease.
    Zhang DY; Zhu L; Liu HN; Tseng YJ; Weng SQ; Liu TT; Dong L; Shen XZ
    Drug Des Devel Ther; 2019; 13():2249-2270. PubMed ID: 31308634
    [No Abstract]   [Full Text] [Related]  

  • 16. Nuclear receptors and nonalcoholic fatty liver disease.
    Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
    Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-Associated Changes in Bile Acid Profiles and Links to Altered Gut Microbiota.
    Joyce SA; Gahan CG
    Dig Dis; 2017; 35(3):169-177. PubMed ID: 28249284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of the Gut Microbiota in Bile Acid Metabolism.
    Ramírez-Pérez O; Cruz-Ramón V; Chinchilla-López P; Méndez-Sánchez N
    Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s15-s20. PubMed ID: 29080339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between gut bacteria and bile in health and disease.
    Long SL; Gahan CGM; Joyce SA
    Mol Aspects Med; 2017 Aug; 56():54-65. PubMed ID: 28602676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gut microbiota at the intersection of bile acids and intestinal carcinogenesis: An old story, yet mesmerizing.
    Liu T; Song X; Khan S; Li Y; Guo Z; Li C; Wang S; Dong W; Liu W; Wang B; Cao H
    Int J Cancer; 2020 Apr; 146(7):1780-1790. PubMed ID: 31291465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.